Browsing by Author "Hiller, L"
Now showing items 1-2 of 2
Issue Date | Title | Author(s) |
---|---|---|
6 June 2019 | 6 versus 12 months of adjuvant trastuzumab in patients with HER2 positive breast cancer (PERSEPHONE): definitive 4-year disease-free survival results of an open label randomised phase 3 non-inferiority trial. | Earl, HM; Hiller, L; Vallier, A; et al. |
2 September 2020 | Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT | Earl, H; Hiller, L; Vallier, A-L; et al. |